Tipifarnib in Treating Young Patients With Refractory Leukemia

Key facts

Sponsor

National Institutes of Health Clinical Center (CC)

Principal Investigator

Brigitte C. Widemann, MD

National Cancer Institute (NCI)

Intervention

tipifarnib(drug)

Eligibility

21 years · All sexes

Timeline

2001 – 2005

Study locations (30)

• Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• UCSF Comprehensive Cancer Center, San Francisco, California, United States
• Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
• Children's National Medical Center, Washington D.C., District of Columbia, United States
• Shands Cancer Center at the University of Florida Health Science Center, Gainesville, Florida, United States
• AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
• MBCCOP-Medical College of Georgia Cancer Center, Augusta, Georgia, United States
• Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
• Riley Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States
• Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center, Kansas City, Kansas, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI) · Children's Oncology Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute biphenotypic leukemia

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07517510
  HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
  Guangdong Second Provincial General Hospital
• RECRUITINGPHASE1, PHASE2NCT07356154
  A Study of Revumenib and Mezigdomide in People With Leukemia
  Memorial Sloan Kettering Cancer Center
• RECRUITINGNCT07537738
  Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia
  Peking University People's Hospital
• RECRUITINGPHASE1, PHASE2NCT05589896
  A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
  Ossium Health, Inc.
• RECRUITINGNANCT05794880
  MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
  Medical College of Wisconsin
• ACTIVE NOT RECRUITINGPHASE2NCT03399773
  Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE1, PHASE2NCT04797767
  Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
  University of Washington
• ACTIVE NOT RECRUITINGPHASE2NCT04975919
  Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
  M.D. Anderson Cancer Center

See all trials for Acute biphenotypic leukemia →